Anti-inflammatory Synergy from the Sea
Seanergy is a clinical stage pharmaceutical company developing a new category of topical therapeutics for treatment of inflammatory and other skin conditions.
Our patented technology is based on the discovery of a synergistic mechanism between anti-inflammatory APIs and Sulphated Polysaccharides extracted from algae.
SPS/Algae
Sulphated Polysaccharides (SPS), secreted by algae, have been broadly used in pharmaceuticals and cosmetics as inactive ingredients. Seanergy discovered their unique interaction with anti-inflammatory APIs – the core of our innovation and proprietary IP.
We are focused exploring the potential of SPS and delivering it
to patients.
Synergy
The combination of SPS with known anti-inflammatory active pharmaceutical ingredients (APIs) is generating a surprisingly potent therapeutic effect. Ex-vivo and in-vivo we see dramatic improvement across a variety of clinical and histological parameters. We are now taking this discovery to the clinic with an aim to improve patients’ lives by enhancing potency while reducing side effects.
Topical inflammations
Seanergy’s innovative topical therapeutics will touch the lives of many millions. Patients suffering from dermatological and auto-immune diseases including Atopic Dermatitis, Psoriasis, Alopecia Areata, Lichen Planus, Seborrhea and numerous other inflammatory skin conditions will now be able to receive better, safer and quicker relief.
Technology
The discovery of the synergistic activity of SPS with anti-inflammatory agents has opened the door to a variety of applications. Our technology is transforming these synergistic combinations into topical therapeutics for inflammatory conditions of the skin in dermatological, autoimmune, other diseases.
In-vitro assessment of synergistic potential
of the SPS with a selected API
Formulation of SPS-based vehicles for
with the selected API
Clinical PoC study
Seanergy was founded in the unique framework of Mii Fund and Labs. The company is managed and operated by its founders together with the Mii team at the Mii Labs R&D center in Rehovot, near the Weizmann Institute of Science. This ecosystem has granted the company access to resources far beyond the reach of a “common” startup company.
Product pipeline
SNG100
Mild to moderate Atopic Dermatitis
SNG300
Severe Atopic Dermatitis
Founders
Dr. Doron Friedman,
Co-Founder & Managing Director
With more than 80 patents, many of them in the field of drug delivery systems, Doron is one of the most active pharma inventors around. His innovations are behind drugs selling under some of the world’s leading brands — products such as Lotemax™, Scytera™, Finacea™ and others. In MII Doron is an investor and inventor. He is one of the founders of MII, and the inventor behind a couple of its portfolio companies.
With a PhD in pharmaceutical sciences from the School of Pharmacy at the Hebrew University in Jerusalem, Doron has published over twenty peer-reviewed papers and over eighty patents in the field of drug delivery systems. Doron is the proud inventor of Lotemax™, Scytera™ and Finacea™ among others. He has also served as CTO at Pharmos Corp., and was a co-founder of Foamix Ltd (NASDAQ FOAMX), and ICDPharma Ltd.
Dr. Friedman is a co-founder of Foamix (NASDAQ FOAMX), ICD Pharma, Seanergy Dermatology and Foillcle Pharma. Formerly he has served as VP R&D of Lipocure and has led R&D in several other companies. Doron was a research associate at the liposomes and membrane laboratory at the Hebrew University of Jerusalem and a lecturer at the School of Engineering at the Hebrew University of Jerusalem. He held a post doctoral position at the School of Pharmacy Ann-Arbor, Michigan in Prof Gordon Amidon’s laboratories.
Education:
Doron holds a Ph.D. in Pharmaceutical Sciences from the Hebrew University Jerusalem.
Eran Perry,
Co-Founder & Managing Director
For the past 15 years Eran has been intricately involved in healthcare innovation, both as an entrepreneur and as a venture capital investor.
Eran is deeply rooted in the Israeli life-science ecosystem as a co-founder and board member of several pharmaceutical companies including ICD Pharma, Musli Thyropeutics, Seanergy Dermatology, Follicle Pharma, and others. He serves as the Chairman of the Investment Committee.
Formerly, Eran served as a Managing Director and Partner of Israel Healthcare Ventures (IHCV), a healthcare focused venture capital group, as a consultant in McKinsey & Company, serving clients worldwide in the Pharmaceutical, Telecom, and Government sectors, and as a member of the Global Marketing group at Novartis Oncology in New Jersey, USA.
Before moving to private sector, Eran served in the Israeli Ministry of Justice, as a Senior Advisor to the Director General of the Ministry.
Education:
Eran holds an MBA from Columbia University, an LL.B. in Law from Tel Aviv University, and a B.Sc. in Mathematics and Computer Science from Tel Aviv University.
Scientific Advisory Board
Dr. Linda Stein Gold, MD
Linda Stein Gold, MD, is Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, as well as Division Head of Dermatology at Henry Ford Health System in West Bloomfield, Michigan.
Prof. Arie Ingber
Prof. Ingber is a senior Dermatologist at the Department of Dermatology. Hadassah University Hospital, Jerusalem, Israel.
Mark Lebwohl, MD
Mark Lebwohl, MD, is the Kimberly and Eric J. Waldman Professor and Chairman, Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York, USA
Amy Paller, M.S., M.D.
Amy Paller, M.S., M.D. is the Walter J. Hamlin Professor and Chair, Professor of Pediatrics, and Director of the NIH-funded Skin Disease Research Center at Northwestern University’s Feinberg School of Medicine.
Lawrence F. Eichenfield M.D.
Lawrence F. Eichenfield, M.D. is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital–San Diego, Vice Chair of the Department of Dermatology and Professor of Dermatology and Pediatrics at the University of California, San Diego (UCSD) School of Medicine.
